{
    "clinical_study": {
        "@rank": "13287", 
        "arm_group": [
            {
                "arm_group_label": "Active", 
                "arm_group_type": "Experimental", 
                "description": "topical treatment"
            }, 
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "topical treatment"
            }
        ], 
        "brief_summary": {
            "textblock": "A topical treatment applied twice daily for 4 weeks to induce disappearance   of facial\n      actinic keratosis (AK). First 4 weeks treatment  (visit 1, 2 and 3 at 0,2 an 4 weeks)\n      treated as a double blind parallel study. From weeks 4 to 7 (visit 3 to visit 4) all\n      patients to be treated by the active component."
        }, 
        "brief_title": "Evaluation of a Topical Treatment for Actinic Keratosis", 
        "completion_date": {
            "#text": "August 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Actinic Keratosis of Face and Scalp", 
        "condition_browse": {
            "mesh_term": [
                "Keratosis", 
                "Keratosis, Actinic"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Males or females 30 to 90 years old, inclusive, in good general health\n\n          -  Clinical diagnosis of Actinic Keratosis\n\n          -  At least 2 clinically diagnosed, 3-15 mm AK lesions on face or scalp\n\n          -  Patient is competent to understand and sign a consent form, and is willing and able\n             to follow study procedures and attend all visits\n\n          -  Female patients of childbearing potential must have a negative urine pregnancy test\n             prior to receiving study medication\n\n          -  Sexually active women of childbearing potential participating in the study must use a\n             medically acceptable form of contraception\n\n          -  Pharmacologic methods of contraception should be stable for 1 month prior to Visit 1\n             and be maintained at same dose during the study\n\n        Exclusion Criteria:\n\n          -  Patients who had been treated with: 5-FU, diclofenac, retinoids, ingenol mebutate or\n             imiquimod within 4 weeks of study, immunomodulators, or interferon/interferon\n             inducers or systemic immunosuppressants within 8 weeks of study, cryodestruction,\n             curettage, photodynamic therapy, surgical excision on the treatment area within 4\n             weeks of study, systemic cancer therapy, UVA therapy, UVB therapy, laser abrasion,\n             dermabrasion\n\n          -  History of hereditary angio-edema, Epilepsy or Parkinson's Disease\n\n          -  Erythroderma or history of immunodeficiency disorders\n\n          -  Pregnancy, lactation or patient who is not practicing effective contraception\n\n          -  History of alcohol and drug abuse within 5 years of screening\n\n          -  Known hypersensitivity or previous allergic reaction to any of the components of the\n             study medication\n\n          -  Having a member of the same household in the trial\n\n          -  Patient has participated in an investigational clinical, surgical, drug or device\n             study within the past 30 days\n\n          -  Patients who in the opinion of the investigator should not be included in the study\n             for any reason, including inability to follow procedures"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "90 Years", 
            "minimum_age": "30 Years"
        }, 
        "enrollment": {
            "#text": "50", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "July 31, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01921907", 
            "org_study_id": "AD17137"
        }, 
        "intervention": [
            {
                "arm_group_label": "Active", 
                "intervention_name": "AD17137 topical treatment", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Placebo", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }
        ], 
        "is_fda_regulated": "No", 
        "keyword": [
            "Actinic keratosis", 
            "topical", 
            "dermatology", 
            "treatment", 
            "clinical study", 
            "double blinded"
        ], 
        "lastchanged_date": "August 12, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Tel Aviv", 
                    "country": "Israel", 
                    "zip": "6495301"
                }, 
                "name": "Maccabi Health Clinic"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Israel"
        }, 
        "number_of_arms": "2", 
        "official_title": "Phase 2 Double-blind, Randomized, Placebo-controlled, Parallel Group, Multi-center Study", 
        "overall_contact": {
            "email": "dasc01@yahoo.com", 
            "last_name": "Avi Dascalu, M.D., Ph.D.", 
            "phone": "+97236099005"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Israel: Ministry of Health"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "June 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Complete Clearance (100% of AK lesions) from baseline (Visit 1) to Visits 3 and 4.  Complete Clearance (100% of AK lesions) from baseline (Visit 1) to Visits 3 and 4.", 
            "safety_issue": "No", 
            "time_frame": "baseline to Week 7"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01921907"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Partial Clearance (75% of AK lesions) from baseline (Visit 1) to Visits 3 and 4.", 
                "safety_issue": "No", 
                "time_frame": "baseline to Week 7"
            }, 
            {
                "measure": "Mean change in lesion size", 
                "safety_issue": "No", 
                "time_frame": "baseline to Week 7"
            }, 
            {
                "measure": "Change in Investigator Global Assessment", 
                "safety_issue": "No", 
                "time_frame": "baseline to Week 7"
            }, 
            {
                "measure": "Mean change in lesion number", 
                "safety_issue": "No", 
                "time_frame": "baseline to Week 7"
            }, 
            {
                "measure": "Change in Patient Global Assessment", 
                "safety_issue": "No", 
                "time_frame": "baseline to Week 7"
            }
        ], 
        "source": "Assuta Hospital Systems", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Assuta Hospital Systems", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "July 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "July 2013"
    }
}